Alector (ALEC) to Release Earnings on Thursday

Alector (NASDAQ:ALEC) is expected to release its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.24) per share and revenue of $1.4280 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Alector (NASDAQ:ALEC) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.08. The company had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $9.67 million. Alector had a negative net margin of 680.83% and a negative return on equity of 295.17%. On average, analysts expect Alector to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Alector Stock Performance

NASDAQ:ALEC opened at $1.52 on Thursday. The company has a fifty day simple moving average of $1.76 and a two-hundred day simple moving average of $2.02. The company has a market cap of $168.77 million, a price-to-earnings ratio of -1.28 and a beta of 0.60. The company has a quick ratio of 5.25, a current ratio of 5.25 and a debt-to-equity ratio of 0.80. Alector has a 52 week low of $1.09 and a 52 week high of $3.40.

Insiders Place Their Bets

In other news, CEO Arnon Rosenthal sold 87,216 shares of the stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $1.97, for a total value of $171,815.52. Following the transaction, the chief executive officer owned 2,367,206 shares in the company, valued at approximately $4,663,395.82. This represents a 3.55% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Neil Lindsay Berkley sold 19,360 shares of the business’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $1.97, for a total value of $38,139.20. Following the sale, the chief financial officer owned 379,900 shares of the company’s stock, valued at approximately $748,403. The trade was a 4.85% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 115,760 shares of company stock worth $227,734. 8.30% of the stock is owned by insiders.

Institutional Trading of Alector

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Prudential Financial Inc. purchased a new stake in shares of Alector during the 2nd quarter worth approximately $30,000. Virtu Financial LLC purchased a new position in shares of Alector in the 4th quarter valued at $34,000. Dynamic Technology Lab Private Ltd acquired a new stake in Alector during the 4th quarter worth $40,000. Oxford Asset Management LLP acquired a new stake in Alector during the 4th quarter worth $67,000. Finally, Quadrature Capital Ltd purchased a new stake in Alector in the fourth quarter valued at $97,000. Institutional investors and hedge funds own 85.83% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on ALEC shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alector in a report on Monday, May 4th. Morgan Stanley reaffirmed an “underweight” rating and issued a $2.00 price target on shares of Alector in a research report on Monday, May 4th. Wall Street Zen raised Alector from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Cantor Fitzgerald upgraded shares of Alector from a “neutral” rating to an “overweight” rating in a research note on Wednesday, April 15th. Three analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $3.62.

About Alector

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.